Forging the Future

 

​     GRIN-X is the intersection for Genetics, Robotics, Information and Nanotechnology. 

  • Futurists predict that in the near decade GRIN will completely transform the market space.

  • Never before imagined products, therapies, technologies and markets will emerge.

  • Conventional regulations, traditional financing, and corporate models will be disrupted.

      Benefits

Via our corporate strategy and competitive intelligence services, we provide emerging technology pathfinders, key stake holders, and visionary investors,  a road map to navigate the human and business terrain, to achieve successful emergence of new medicines, treatments and technology products.

Since 2014 every GRIN-X client exceeded goals. For example: 

 

Cancer Prevention Pharmaceuticals - 2018 

In April 2018, UK-based Mallinckrodt had exercised its option to the license agreement, and paid CPP $10 million to support the pivotal Phase 3 clinical trial of CPP-1X/sul in patients with the orphan disease familial adenomatous polyposis (FAP). 

 

Calimmune - 2017 

Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Calimmune, Inc., a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California and Sydney, Australia for an upfront payment of $91 million, with possible milestone payments reaching an eventual total of $416 million.

 

GRIN-X

info@grin-x.com

520-241-7690

8987 E Tanque Verde Rd

St 309-245

Tucson, AZ 85749